Results 71 to 80 of about 38,235 (163)

Oxidative Stress and DNA Epigenetic Modifications in Cancer: Mechanisms and Targeted Therapeutics

MedComm – Oncology, Volume 5, Issue 2, June 2026.
Reactive oxygen species (ROS) modulate DNA methyltransferases (DNMTs), ten‐eleven translocation family proteins (TETs) and their cofactors, reshaping 5‐methylcytosine (5mC)/5‐hydroxymethylcytosine (5hmC)/5‐formylcytosine (5fC) landscapes and gene expression in cancer cells. In turn, epigenetic control of antioxidant and metabolic pathways feeds back on
Xishan Yang, Qitai Chen, YuJie Yu, Yi Zang, Rujia Zheng, Zhe Zhang, Shuaijun Lu, Li Zhou   +7 more
wiley   +1 more source

A conceptually new treatment approach for relapsed glioblastoma: Coordinated undermining of survival paths with nine repurposed drugs (CUSP9) by the International Initiative for Accelerated Improvement of Glioblastoma Care [PDF]

, 2017
Kast, Richard E. et al.To improve prognosis in recurrent glioblastoma we developed a treatment protocol based on a combination of drugs not traditionally thought of as cytotoxic chemotherapy agents but that have a robust history of being well-tolerated ...
Halatsch, Marc-Eric, Kast, Richard E., Muñoz Sáez, Miguel   +2 more
core   +1 more source

Management of Adult Patients With Isocitrate Dehydrogenase‐Mutant Gliomas in Australia: An Expert Position Statement From the Cooperative Trials Group for Neuro‐Oncology

Asia-Pacific Journal of Clinical Oncology, Volume 22, Issue 3, Page 392-403, June 2026.
Following maximal surgery when feasible, management of adult patients with isocitrate dehydrogenase (IDH)‐mutant glioma is complex and should be considered in a neuro‐oncology multidisciplinary context balancing disease control versus potential treatment‐associated toxicities. Options include continued surveillance, radiation therapy, chemotherapy, and/
Mark B. Pinkham, Hao‐Wen Sim, Rosalind L. Jeffree, Arian Lasocki, Dianne M. Legge, Frank Saran, Laveniya Satgunaseelan, Hui K. Gan   +7 more
wiley   +1 more source

Isocitrate Dehydrogenase Mutations in Cancer: From Bench to Bedside Applications

MedComm, Volume 7, Issue 5, May 2026.
Mutant isocitrate dehydrogenase affects multiple cancer types. Alterations in IDH1 and IDH2 result in abnormal enzyme activity, leading to the overproduction of D‐2‐hydroxyglutarate (D‐2HG). This metabolite disrupts cellular metabolism and epigenetic regulation, driving cancer initiation, progression, and metastasis.
Yuhan Fang, Xiaoqing Wang, Kai Luo, Tikam Chand Dakal, He Bai, Caiming Xu, Guixin Zhang   +6 more
wiley   +1 more source

Evaluation of the Dual Impact of Nanotechnologies on Health and Environment Through Alternative Bridging Models

Advanced Healthcare Materials, Volume 15, Issue 15, 17 April 2026.
This review explores how alternative invertebrate and small‐vertebrate models advance the evaluation of nanomaterials across medicine and environmental science. By bridging cellular and organismal levels, these models enable integrated assessment of toxicity, biodistribution, and therapeutic performance.
Marie Celine Lefevre, Margherita Bernardeschi, Matteo Battaglini, Gianni Ciofani   +3 more
wiley   +1 more source

Combining Small‐Molecular Compounds With CAR T‐Cell Therapy: Novel Strategies for Enhanced Cancer Immunotherapy

Cancer Innovation, Volume 5, Issue 2, April 2026.
Chimeric antigen receptor (CAR) T‐cell therapy, although revolutionary for haematological malignancies, faces significant challenges, including T‐cell exhaustion, limited persistence, and treatment‐related toxicity. The integration of small‐molecule compounds offers a promising strategy to overcome these limitations.
Rangzi Yi, Zijian Zhang, Yang Yang, Haichuan Zhu   +3 more
wiley   +1 more source

Neoadjuvant anti-PD-1 immunotherapy promotes a survival benefit with intratumoral and systemic immune responses in recurrent glioblastoma. [PDF]

, 2019
Glioblastoma is the most common primary malignant brain tumor in adults and is associated with poor survival. The Ivy Foundation Early Phase Clinical Trials Consortium conducted a randomized, multi-institution clinical trial to evaluate immune responses ...
Arrillaga-Romany, Isabel C, Butowski, Nicholas A, Clarke, Jennifer L, Cloughesy, Timothy F, Cohen, Adam L, Colman, Howard, Davidson, Tom B, de Groot, John F, Du, Lin, Ellingson, Benjamin M, Gaffey, Sarah C, Hugo, Willy, Kaley, Thomas J, Kawaguchi, Eric S, Lee, Alexander H, Lee, Eudocia Q, Li, Gang, Liau, Linda M, Mellinghoff, Ingo K, Mochizuki, Aaron Y, Nghiemphu, Phioanh L, O'Brien, Barbara J, Orpilla, Joey R, Prins, Robert M, Reardon, David A, Rytlewski, Julie A, Sanders, Catherine M, Wang, Anthony C, Wen, Patrick Y, Yong, William H   +29 more
core  

Novel insights into extracellular vesicles: An update on biomolecules, immunomodulation and clinical strategies in skin melanoma

Clinical and Translational Medicine, Volume 16, Issue 4, April 2026.
Extracellular vesicles mediate melanoma progression by transferring biomolecules (proteins, nucleic acids) that reshape the tumour microenvironment, promote immune evasion and drive metastasis. They also serve as diagnostic biomarkers and engineered therapeutic carriers for targeted therapy.
Junshu Li, Wencheng Zhou, Ying Cen, Yong Qing   +3 more
wiley   +1 more source

The Homeobox Genes: Classification, Regulation, Biological Functions, and Diseases

MedComm, Volume 7, Issue 4, April 2026.
Overview of the homeobox gene superfamily and its pathophysiological roles. The homeobox superfamily comprises several major classes, including ANTP, PRD, TALE, LIM, POU, and others. Among these, the HOX clusters (A–D) play critical roles in embryonic development specifically in conferring cellular identity, regulating morphogenesis, and guiding axial ...
Maedeh Dadzadi, Shahin Ramazi, Mona Darvazi, Sepideh Yoosefi, Melika Abbasi, Shirin Farsad   +5 more
wiley   +1 more source

Development of a Clinically Relevant Temozolomide-Resistant Human Glioblastoma A-172 Cell Line

Background: Glioblastoma is the most aggressive and deadly form of brain cancer, with a median survival of approximately 14 months. A major factor contributing to an unfavorable prognosis is the development of resistance to temozolomide (TMZ), the current first-line chemotherapeutic drug for glioblastoma. Thus, developing reliable preclinical models of
Pajović, Milica, Dinić, Jelena, Lupšić, Ema, Jovanović Stojanov, Sofija, Grozdanić, Marija, Pešić, Milica, Podolski-Renić, Ana, Dragoj, Miodrag   +7 more
openaire   +1 more source